Shanghai Genext Pharmaceutical Technology

Genext is a Shanghai-based transplant-focused healthcare company that develops, manufactures, and commercializes products used in organ transplantation. Its business spans transplant therapeutics, in vitro diagnostics, therapeutic drug monitoring, organ preservation and perfusion equipment, and related surgical accessories. The company appears to generate revenue primarily from commercialized transplantation products rather than from a traditional innovative drug pipeline. Genext has also expanded internationally through its acquisition of Lifeline Scientific, adding organ preservation and perfusion capabilities for organs, tissues, and cells. The company sought a STAR Market IPO in China, but its listing review was terminated in April 2024 after the company and its sponsor withdrew the application. Overall, Genext is best characterized as a commercial-stage transplant medtech and diagnostics company with some pharmaceutical distribution/manufacturing exposure rather than a classic R&D-stage biotech.